We first assayed the prostate cancer stem cell markers CD133 and CD44 to determine whether increasing cellular quiescence could increase the fraction of CD133/CD44 double positive potential cancer stem cells (Jung et al., 2016). The gene discussed is CD44; the disease is prostate carcinoma.